109 recruiting, 105 completed, 65 terminated, 65 unknown. 224 Phase 2, 186 Phase 1, 37 Phase 3, 23 Not applicable, 10 Early Phase 1.
Follow this condition Literature Review of Triple Negative Breast Cancer trials Research Report on Triple Negative Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. Gemcitabine (1000 mg/m^2), Paclitaxel 80 mg/m2 weekly - Triple Negative Breast Cancer, Metastatic Triple-negative Breast Cancer | Phase 2 | Not yet recruiting | The University of The West Indies | 750 | 2027-06-01 | 2026-09-22 |
| Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) [18F]FMISO-PET with contrast-enhanced MRI - Triple Negative Breast Cancer | Early Phase 1 | Recruiting | University of Alabama at Birmingham | 20 | 2027-06-01 | 2026-08-17 |
| Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. BLEX 404 Oral Liquid - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | BioLite, Inc. | 44 | 2027-01-01 | 2026-04-13 |
| A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast Cancer Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043, Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin） - Triple Negative Breast Cancer | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 550 | 2026-11-30 | 2026-10-19 |
| Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial Paclitaxel + Carboplatin, Pembrolizumab - Triple Negative Breast Cancer, Blood and Image Guided | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 200 | 2026-11-05 | 2026-05-28 |
| Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients Paclitaxel, Carboplatin, Pembrolizumab - Triple Negative Breast Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 30 | 2026-10-01 | 2026-09-04 |
| Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer Neoadjuvant Chemotherapy, Radiation Therapy, MRI - Breast Cancer, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 84 | 2026-09-15 | 2026-06-24 |
| A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer Trastuzumab Rezetecan for Injection, Adebrelimab Injection, Capecitabine tablets - Triple Negative Breast Cancer | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 1000 | 2026-09-02 | 2026-09-09 |
| Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC Carboplatin, Docetaxel, Doxorubicin - Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Not yet recruiting | University of Kansas Medical Center | 110 | 2026-09-01 | 2026-08-04 |
| Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression TheraBionic P1 - Triple Negative Breast Cancer | Not applicable | Not yet recruiting | Barbara Ann Karmanos Cancer Institute | 24 | 2026-09-01 | 2026-06-29 |
| GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours Fludarabine, Cyclophosphamide, GCAR1 - Alveolar Soft Part Sarcoma, Renal Cell Carcinoma | Phase 1 | Recruiting | Canadian Cancer Trials Group | 30 | 2026-08-30 | 2026-10-16 |
| A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer CMF Regimen, Paclitaxel - Adenocarcinoma of the Breast, Breast Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 76 | 2026-08-11 | 2026-08-17 |
| Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy Omission of surgery - Triple Negative Breast Cancer, Non-Metastatic | Not applicable | Not yet recruiting | Institut Curie | 150 | 2026-08-01 | 2026-06-03 |
| Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC AI-analysis on diagnostic and surgical specimens - Triple Negative Breast Cancer | Not yet recruiting | Institute of Cancer Research, United Kingdom | 50 | 2026-08-01 | 2026-03-27 | |
| Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype Dexamethasone, Bortezomib, LENALIDOMIDE - Multiple Myeloma, Triple Negative Breast Cancer | Phase 1 | Recruiting | Andrew Hantel, MD | 90 | 2026-07-30 | 2026-08-17 |
| A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors HH160 - Solid Tumor, Non-small Cell Lung Cancer | Phase 1 | Recruiting | Huahui Health | 299 | 2026-06-11 | 2026-08-21 |
| ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer ARX788, Computed Tomography (CT), Biospecimen Collection - HER2 Low Breast Carcinoma, Triple Negative Breast Cancer | Phase 2 | Recruiting | Laura Huppert, MD, BA | 36 | 2026-06-05 | 2026-06-11 |
| Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging ctDNA-guided imaging surveillance, Standard - Triple Negative Breast Cancer, Surveillance | Not applicable | Not yet recruiting | Sunnybrook Health Sciences Centre | 30 | 2026-05-01 | 2026-03-17 |
| Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC Zimberelimab (AB122), Domvanalimab (DOM), Sacituzumab Govitecan (SG) - Triple Negative Breast Cancer, PDL-1 Positive | Phase 2 | Withdrawn | MedSIR | 2026-04-01 | 2026-05-01 | |
| A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care JSKN016 Injection, Eribulin Mcsilate Injection, Vinorelbine Tartrate Injection - Triple Negative Breast Cancer | Phase 3 | Recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 364 | 2026-03-17 | 2026-04-16 |
Showing 20 of 451. Sign in to see all of them.
Triple Negative Breast Neoplasms (451) · Breast Neoplasms (155) · Carcinoma, Non-Small-Cell Lung (81) · Ovarian Neoplasms (59) · Colorectal Neoplasms (45) · Squamous Cell Carcinoma of Head and Neck (44) · Endometrial Neoplasms (39) · Melanoma (39) · Neoplasm Metastasis (38) · Carcinoma, Renal Cell (32) · Neoplasms (31) · Stomach Neoplasms (30) · Uterine Cervical Neoplasms (27) · Pancreatic Neoplasms (25) · Urinary Bladder Neoplasms (22)
Skin Diseases (451) · Skin and Connective Tissue Diseases (451) · Breast Diseases (450) · Neoplasms by Site (450) · Neoplasms (420) · Breast Neoplasms (296) · Neoplasms by Histologic Type (109) · Urogenital Diseases (101) · Female Urogenital Diseases (99) · Female Urogenital Diseases and Pregnancy Complications (99) · Urogenital Neoplasms (99) · Neoplasms, Glandular and Epithelial (96) · Respiratory Tract Neoplasms (94) · Lung Diseases (93) · Respiratory Tract Diseases (93)
pembrolizumab (71) · Carboplatin (56) · Paclitaxel (52) · Cyclophosphamide (48) · Capecitabine (29) · Doxorubicin (23) · Gemcitabine (22) · 130-nm albumin-bound paclitaxel (20) · atezolizumab (17) · sacituzumab govitecan (16) · Cisplatin (14) · Docetaxel (13) · Epirubicin (13) · eribulin (12) · Nivolumab (10)
Fudan University (13) · Novartis Pharmaceuticals (9) · Chinese Academy of Medical Sciences (6) · H. Lee Moffitt Cancer Center and Research Institute (6) · Memorial Sloan Kettering Cancer Center (6) · Washington University School of Medicine (6) · Gilead Sciences (5) · Institut Curie (5) · MedSIR (5) · AbbVie (4) · Dana-Farber Cancer Institute (4) · Eli Lilly and Company (4) · European Institute of Oncology (4) · Jiangsu HengRui Medicine Co., Ltd. (4) · Massachusetts General Hospital (4)
United States (233) · China (81) · Spain (56) · France (49) · United Kingdom (40) · Italy (37) · Australia (31) · Canada (30) · South Korea (30) · Belgium (29) · Germany (23) · Japan (20) · Taiwan (19) · Israel (14) · Netherlands (11)
David Page, MD (4) · Kari Wisinski, MD (4) · Kathy Miller, MD (3) · Zhong-yu Yuan, M.D. (3) · Alberto Zambelli, MD (2) · Eileen Connolly, MD (2) · Jackie Walling, MBChB, PhD (2)
PMID 32101663, PMID 24529560, PMID 32450725, PMID 32966830, PMID 35728046, PMID 38979716, PMID 17135638, PMID 17785706, PMID 19299237, PMID 19647220, PMID 19917869, PMID 20556505, PMID 21304525, PMID 21437909, PMID 21483002, PMID 21671016, PMID 21841316, PMID 22049225, PMID 23274845, PMID 23341518, PMID 23778140, PMID 24063698, PMID 24401929, PMID 25071121, PMID 25092775, PMID 25214542, PMID 25534375, PMID 25847929, PMID 25915780, PMID 25944802, PMID 26106073, PMID 26341640, PMID 26515496, PMID 26541586, PMID 26942062, PMID 27324108, PMID 27713176, PMID 27872127, PMID 27935867, PMID 28291390, PMID 28302091, PMID 28548889, PMID 28558150, PMID 28564564, PMID 28679770, PMID 29045526, PMID 29109077, PMID 29322091, PMID 29380207, PMID 29423221
2018 (9), 2023 (9), 2016 (7), 2017 (7), 2014 (6), 2025 (4), 2019 (3), P30CA012197 (1), P30CA014089 (1), P50CA058223 (1), R01CA240983 (1), R01CA290013 (1), R01HL159393 (1)